MS Stratification via CD27- Th1 Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multiple sclerosis (MS) treatments are largely nonspecific and associated with significant side effects, failing to effectively target the root cause of the autoimmune response, and there is a need for personalized therapeutic approaches that account for individual genetic and immune system characteristics.
Innovation Solution
A method involving the detection of CD27− Th1 CD4+ cells in body fluids, particularly blood or cerebrospinal fluid, and responsiveness to GDP-L-fucose synthase (GDP-L-FS) or its fragments, derivatives, and splice variants, to tailor antigen-specific tolerization strategies for MS patients, using these biomarkers to guide personalized treatment regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonspecific immunosuppressive therapies are used to treat multiple sclerosis, then the autoimmune response is suppressed, but significant side effects occur and beneficial immune functions are compromised
Solution Approach 1:
The patent segments the immune response by identifying and targeting specific pathogenic T cell subsets (CD27− Th1 CD4+ cells) rather than suppressing the entire immune system. This is achieved through detecting specific biomarkers and administering antigen-specific tolerization therapies that selectively modulate only the harmful autoreactive cells while preserving beneficial immune functions.
Solution Approach 2:
The patent applies local quality by creating personalized treatment regimens based on individual patient biomarker profiles. The therapy is tailored to each patient's specific immune characteristics, such as their responsiveness to GDP-L-fucose synthase or other autoantigens, ensuring that the immunosuppression is localized to the specific pathogenic pathways present in that patient rather than applying blanket immunosuppression.
2Adaptability or versatility
If personalized therapeutic approaches are developed to target individual genetic and immune characteristics, then treatment specificity is improved, but device and procedure complexity increases
Solution Approach 1:
The patent implements preliminary action by performing biomarker detection and patient stratification before initiating treatment. The method detects specific T cell phenotypes and autoantigen responses in advance, allowing the treatment regimen to be customized based on pre-assessed immune characteristics. This upfront personalization simplifies the overall treatment process by avoiding trial-and-error approaches.
Solution Approach 2:
The patent utilizes parameter changes by measuring specific immunophenotypic markers (such as CD27 expression levels, Th1 differentiation status, and autoantigen reactivity) to categorize patients into distinct subgroups. These parameter-based classifications enable the selection of appropriate antigen-specific tolerization strategies without requiring overly complex diagnostic procedures.
Data Source
AI summary
The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient. The invention also relates to the field of antigen specific immunotherapies, such as the induction of tolerance.